--- title: "Nuvation Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 83.23 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285116361.md" datetime: "2026-05-04T20:23:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285116361.md) - [en](https://longbridge.com/en/news/285116361.md) - [zh-HK](https://longbridge.com/zh-HK/news/285116361.md) --- # Nuvation Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 83.23 M Revenue: As of FY2026 Q1, the actual value is USD 83.23 M, beating the estimate of USD 62.34 M. EPS: As of FY2026 Q1, the actual value is USD 0.01, beating the estimate of USD -0.0004. EBIT: As of FY2026 Q1, the actual value is USD 5.481 M. #### Net Product Revenue Nuvation Bio Inc. reported net product revenue of $18.5 million for the first quarter of 2026, primarily from U.S. sales of IBTROZI, compared to $0 for the three months ended March 31, 2025. #### Collaboration and License Agreements Revenue Collaboration and license agreements revenue for the first quarter of 2026 was $64.7 million, a significant increase from $3.1 million for the same period in 2025. This increase was mainly driven by a $58.7 million increase in license revenue due to an upfront payment from the Eisai agreement, a $2.4 million increase in product supply, and a $1.5 million increase in royalty revenue, partially offset by a $1.0 million decrease in research and development service revenue. Royalty revenue from collaboration agreements for China and Japan amounted to $1.7 million for the quarter. #### Total Revenues Total revenues for the first quarter of 2026 were $83.2 million, up from $3.1 million in the first quarter of 2025. #### Research and Development Expenses Research and development expenses increased to $35.0 million for the first quarter of 2026, compared to $24.6 million for the first quarter of 2025. This rise was primarily due to a $1.5 million increase in salaries and other benefits and an $8.9 million increase in third-party costs related to clinical trials. #### Selling, General and Administrative Expenses Selling, general, and administrative expenses were $38.3 million for the first quarter of 2026, an increase from $35.4 million for the first quarter of 2025. This increase was attributed to a $5.7 million rise in salaries and other benefits and a $0.1 million increase in taxes, partially offset by a $1.7 million decrease in sales and marketing expenses and a $1.2 million decrease in professional fees. #### Total Costs and Expenses Total costs and expenses for the first quarter of 2026 were $79.3 million, compared to $62.1 million for the first quarter of 2025. #### Income (Loss) from Operations Nuvation Bio Inc. reported an income from operations of $3.9 million for the first quarter of 2026, a notable improvement from an operating loss of - $59.0 million in the first quarter of 2025. #### Net Income (Loss) Nuvation Bio Inc. achieved a net income of $5.4 million for the first quarter of 2026, compared to a net loss of - $53.2 million in the comparable period of 2025. #### Cash, Cash Equivalents, and Marketable Securities As of March 31, 2026, Nuvation Bio Inc. had cash, cash equivalents, and marketable securities totaling $533.7 million. #### Operational Highlights and Unique Metrics In the first quarter of 2026, Nuvation Bio Inc. generated $18.5 million in net product revenues for IBTROZI. Over 600 patients have started IBTROZI treatment since its launch in late June 2025, with more than half of the approximately 200 new patients initiating IBTROZI in the first quarter of 2026 being TKI-naïve. The company also acquired global development and commercialization rights for safusidenib from Daiichi Sankyo, including the transfer of its global clinical development program. #### Outlook / Guidance Nuvation Bio Inc. plans to advance the pivotal Phase 3 SIGMA study for safusidenib and provide updates on its drug-drug conjugate platform later this year. The company anticipates the European Medicines Agency (EMA) Marketing Authorisation Application for taletrectinib to follow a standard review timeline and be considered for full approval. ### Related Stocks - [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Financial year ending 31 March 2026 reports final results.](https://longbridge.com/en/news/287166907.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md) - [BioPorto reports Q1 2026 performance in latest update.](https://longbridge.com/en/news/287173693.md)